Patents Assigned to Humanetics Corporation
  • Sensitizing cells to proton radiation
    Patent number: 11779644
    Abstract: Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: October 10, 2023
    Assignees: Humanetics Corporation, Trustees of the University of Pennsylvania
    Inventors: Adam J. Harvey, Michael D. Kaytor, Keith Cengel, Eric Stanton Diffenderfer
  • NANOPARTICLE ISOFLAVONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20220370403
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Application
    Filed: February 10, 2022
    Publication date: November 24, 2022
    Applicant: Humanetics Corporation
    Inventors: Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Protecting tissue and mitigating injury from radiation-induced ionizing events
    Patent number: 11419827
    Abstract: Materials and methods for reducing, preventing, or mitigating the effects of exposure to ionizing radiation are provided herein. In general, the methods can include administering a nanoparticulate genistein composition to a subject identified as having been exposed or at risk of being exposed to ionizing radiation, such as proton radiation.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: August 23, 2022
    Assignee: Humanetics Corporation
    Inventors: Adam J. Harvey, Michael D. Kaytor, John C. Dykstra
  • Sensitizing cells to proton radiation
    Patent number: 11129894
    Abstract: Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: September 28, 2021
    Assignees: - Humanetics Corporation, The Trustees of the University of Pennsylvania
    Inventors: Adam J. Harvey, Michael D. Kaytor, Keith Cengel, Eric Stanton Diffenderfer
  • NANOPARTICLE ISOFLAVONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20210000788
    Abstract: The present invention is directed to formulations of genistein and methods for making and using, the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Application
    Filed: July 21, 2020
    Publication date: January 7, 2021
    Applicant: Humanetics Corporation
    Inventors: Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Nanoparticle isoflavone compositions and methods of making and using the same
    Patent number: 10729674
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: August 4, 2020
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Suspension compositions of physiologically active phenolic compounds and methods of making and using the same
    Patent number: 10314812
    Abstract: The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: June 11, 2019
    Assignee: Humanetics Corporation
    Inventors: David C. Egberg, Michael D. Kaytor, John C. Dykstra
  • NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME
    Publication number: 20190160038
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Application
    Filed: July 3, 2018
    Publication date: May 30, 2019
    Applicant: Humanetics Corporation
    Inventors: Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Method of mitigating long and short term detrimental effects of exposure to low dose ionizing radiation by administration of genistein
    Patent number: 10220018
    Abstract: Mitigation of long and short-term detrimental effects of exposure to low dose ionizing radiation by administration of genistein in the form of a nanosuspension to a mammal in an amount effective for achieving genistein serum levels of between 1-5 ?M in the mammal throughout a time period from exposure to the ionizing radiation to twelve hours after exposure to the ionizing radiation.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: March 5, 2019
    Assignee: Humanetics Corporation
    Inventors: Michael D. Kaytor, John L. Zenk
  • SUSPENSION COMPOSITIONS OF PHYSIOLOGICALLY ACTIVE PHENOLIC COMPOUNDS & METHODS OF MAKING AND USING THE SAME
    Publication number: 20190038593
    Abstract: The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
    Type: Application
    Filed: February 28, 2018
    Publication date: February 7, 2019
    Applicant: Humanetics Corporation
    Inventors: David C. Egberg, Michael D. Kaytor, John C. Dykstra
  • Nanoparticle isoflavone compositions and methods of making and using the same
    Patent number: 10039739
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: August 7, 2018
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Method of mitigating long term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein
    Patent number: 9993455
    Abstract: Mitigation of long term detrimental effects of exposure to medical imaging ionizing radiation by administration of an amount of genistein in the form of a nanosuspension to someone effective for achieving genistein serum levels of between 1-5 ?M in the mammal throughout a time period from exposure to medical imaging ionizing radiation to twelve hours after exposure to medical imaging ionizing radiation.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: June 12, 2018
    Assignee: Humanetics Corporation
    Inventors: Michael D. Kaytor, John L. Zenk
  • Suspension compositions of physiologically active phenolic compounds and methods of making and using the same
    Patent number: 9937148
    Abstract: The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: April 10, 2018
    Assignee: Humanetics Corporation
    Inventors: David C. Egberg, Michael D. Kaytor, John C. Dykstra
  • SUSPENSION COMPOSITIONS OF PHYSIOLOGICALLY ACTIVE PHENOLIC COMPOUNDS & METHODS OF MAKING AND USING THE SAME
    Publication number: 20180000773
    Abstract: The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
    Type: Application
    Filed: September 1, 2017
    Publication date: January 4, 2018
    Applicant: Humanetics Corporation
    Inventors: David C. Egberg, Michael D. Kaytor, John C. Dykstra
  • NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME
    Publication number: 20170304258
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Application
    Filed: July 6, 2017
    Publication date: October 26, 2017
    Applicant: Humanetics Corporation
    Inventors: Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Suspension compositions of physiologically active phenolic compounds and methods of making and using the same
    Patent number: 9782384
    Abstract: The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: October 10, 2017
    Assignee: Humanetics Corporation
    Inventors: David C. Egberg, Michael D. Kaytor, John C. Dykstra
  • Nanoparticle isoflavone compositions and methods of making and using the same
    Patent number: 9724325
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: August 8, 2017
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Nanoparticle isoflavone compositions and methods of making and using the same
    Patent number: 9636322
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: May 2, 2017
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein
    Patent number: 9623003
    Abstract: Mitigation of long and short-term detrimental effects of exposure to medical imaging ionizing radiation by administration of an effective amount of genistein in the form of a nanosuspension to someone within forty eight hours prior to and/or within twelve hours after exposure to medical imaging ionizing radiation.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: April 18, 2017
    Assignee: Humanetics Corporation
    Inventors: Michael D. Kaytor, John L. Zenk
  • NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME
    Publication number: 20160374984
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Application
    Filed: September 7, 2016
    Publication date: December 29, 2016
    Applicant: Humanetics Corporation
    Inventors: Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk